Beijer Group continued its impressive run with yet another all-time high in Q3'22, beating Redeye’s net sales and EBIT estimates. The main difference compared to previous quarters was that both business units performed well simultaneously, with improved sales conversions and a large part of the extra volume going directly down to EBIT, thanks to the group’s operating leverage. The company’s report was welcomed with a deserved jump in the share price and Redeye raises its base case a bit as well.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking.